文献速递免疫规划传染病防控与疫情报告

LP.8.1重组蛋白新冠疫苗S-268025联合角鲨烯佐剂在小鼠中诱导强免疫原性与中和广度

LP.8.1-directed recombinant protein COVID-19 vaccine S-268025, formulated with squalene-based adjuvant A-910823, elicits robust immunogenicity and neutralizing breadth in mice.
PubMed 文献 · Vaccine · 2026-09-22

研究评估了以LP.8.1株抗原和角鲨烯佐剂A-910823配制的重组蛋白疫苗S-268025在小鼠中的免疫原性。结果显示该疫苗诱导针对LP.8.1、XFG、NB.1.8.1和PQ.2.8.1变异株的强效血清中和抗体滴度,中和广度与XFG抗原疫苗相当。LP.8.1疫苗基础免疫影响BA.3.2.2疫苗加强免疫,针对BA.3.2.2假病毒的中和抗体诱导水平有限。

要点

  • S-268025诱导针对LP.8.1、XFG、NB.1.8.1和PQ.2.8.1的中和抗体。
  • 其中和广度与XFG抗原重组蛋白疫苗相当。
  • LP.8.1基础免疫限制BA.3.2.2疫苗加强的中和抗体诱导。

核心结论

  • LP.8.1重组蛋白疫苗S-268025在小鼠中诱导针对多种JN.1衍生变异株的强效中和抗体,支持其用于2026-27季节新冠疫苗方案。

研究设计与样本

  • 小鼠非临床免疫原性研究,比较LP.8.1、XFG和BA.3.2.2抗原重组蛋白疫苗诱导的血清中和抗体。

主要发现

  • S-268025诱导针对LP.8.1、XFG、NB.1.8.1和PQ.2.8.1变异株的强效血清中和抗体滴度。
  • LP.8.1疫苗的中和广度与XFG抗原重组蛋白疫苗相当。
  • BA.3.2.2抗原疫苗诱导的血清中和抗体滴度与LP.8.1和XFG疫苗不同。
  • LP.8.1疫苗基础免疫影响BA.3.2.2疫苗加强免疫,针对BA.3.2.2假病毒的中和抗体诱导水平有限。

临床怎么用

  • 非临床证据支持LP.8.1疫苗用于2026-27季节新冠疫苗免疫方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SARS-CoV-2 continues to evolve by repeatedly undergoing antigenic mutations and evolving into different lineages, evading host immunity. Currently, viruses derived from the JN.1 lineages such as XFG and NB.1.8.1 strains have continued to spread globally, and the BA.3.2.2 strain has also been detected as a new lineage that may have acquired immune evasion capabilities. Here, we demonstrated that a recombinant protein vaccine S-268025, formulated with the LP.8.1 strain antigen and squalene adjuvant A-910823, induced potent serum neutralizing antibody titers against LP.8.1, XFG, NB.1.8.1, and PQ.2.8.1 variants in mice. This neutralizing breadth was comparable to that of a recombinant protein vaccine formulated with the XFG antigen. Intriguingly, the serum neutralizing antibody titers, elicited by the recombinant protein vaccine formulated with the BA.3.2.2 antigen, were shown to differ from those induced by the LP.8.1 and XFG vaccines. Furthermore, the priming series of vaccination with the LP.8.1 vaccine had an impact on the booster immunization with the BA.3.2.2 vaccine, and limited levels of NAbs induction against the BA.3.2.2 pseudovirus were detected. A line of evidence from nonclinical findings supports the efficacy of the LP.8.1 vaccine in COVID-19 vaccine regimens for the 2026-27 seasons.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Saiki S, Kuroiwa M, Hashimoto K, et al. LP.8.1-directed recombinant protein COVID-19 vaccine S-268025, formulated with squalene-based adjuvant A-910823, elicits robust immunogenicity and neutralizing breadth in mice. Vaccine. 2026. PMID: 42784873. doi:10.1016/j.vaccine.2026.129177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。